Lung function decline in COPD

Claudio Tantucci, Denise Modina, Claudio Tantucci, Denise Modina

Abstract

The landmark study of Fletcher and Peto on the natural history of tobacco smoke-related chronic airflow obstruction suggested that decline in the forced expiratory volume in the first second (FEV(1)) in chronic obstructive pulmonary disease (COPD) is slow at the beginning, becoming faster with more advanced disease. The present authors reviewed spirometric data of COPD patients included in the placebo arms of recent clinical trials to assess the lung function decline of each stage, defined according to the severity of airflow obstruction as proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. In large COPD populations the mean rate of FEV(1) decline in GOLD stages II and III is between 47 and 79 mL/year and 56 and 59 mL/year, respectively, and lower than 35 mL/year in GOLD stage IV. Few data on FEV(1) decline are available for GOLD stage I. Hence, the loss of lung function, assessed as expiratory airflow reduction, seems more accelerated and therefore more relevant in the initial phases of COPD. To have an impact on the natural history of COPD, it is logical to look at the effects of treatment in the earlier stages.

Keywords: FEV1; chronic obstructive pulmonary disease; decline; forced expiratory volume in 1 second.

Figures

Figure 1
Figure 1
Modified version of Fletcher and Peto’s graph showing the decline in the forced expiratory volume in the first second (FEV1).
Figure 2
Figure 2
Range of average rate of decline in the forced expiratory volume in the first second (FEV1) of chronic obstructive pulmonary disease patients according to initial severity of airflow reduction. Notes: The dashed segment of the line highlights any stage or part of it where consistent information is still lacking; control data from the UPLIFT (understanding Potential Long-term Impacts on Function with Tiotropium) study were not considered in the analysis. Abbreviation: yr, year.

References

    1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648.
    1. Fletcher C, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. London: Oxford University Press; 1976.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung and Blood Institute; Apr, 2001. (revised 2007)
    1. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63(9):768–774.
    1. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–1823.
    1. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic broncodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272(19):1497–1505.
    1. Pauwels RA, Löfdhal CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1948–1953.
    1. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675–679.
    1. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902–1909.
    1. Jenkins CR, Jones PW, Calverly PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
    1. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease. Ann Intern Med. 2009;151(8):517–527.
    1. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–1178.
    1. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303.
    1. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther. 2005;18(2):75–81.
    1. Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha1- antitrypsin deficiency. Eur Respir J. 2009;33(6):1338–1344.
    1. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192.
    1. Decramer M, Cooper CB. Treatment of COPD: the sooner the better? Thorax. 2010;65(9):837–841.
    1. Curtis RJ, Deyo RA, Hudson LD. Pulmonary rehabilitation in chronic respiratory insufficiency: 7. Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax. 1994;49(2):162–170.
    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir